For the second time in recent months, Pfizer is having to recall hundreds of thousands of bottles of a drug when one was found to contain the wrong tablet. Pfizer says a single 100 mg tablet of Pristiq Extended Release was found in a 50 mg bottle but the drugmaker is taking no chances and is recalling four lots of the the antidepressant drug.
We're accustomed to the fact that U.S. payers shell out more for drugs and vaccines than payers in other countries that have cost-conscious government gatekeepers. But a new analysis by The New York Times shows that, in the vaccines market, pricing is even more schizophrenic than that.
Few people noticed when Pfizer announced kosher certification for its Gaucher disease treatment Elelyso. So the company reposted its press release. And now, the news is getting some media play that could prove just as important in forming patient relationships as the certification itself.
Pfizer has a manufacturing plant underway in Saudi Arabia that is slated to be operating next year. But the drugmaker has just struck a deal that will give it access to additional capacity, as well as products, in that country.
Back in 1989, a court order limited advertising claims for Advil, now owned by Pfizer. But does that order extend to Infants' Advil, which didn't exist at the time? Rival Johnson & Johnson says yes--and it's forced Pfizer to pull one of its ads for that very reason.
After meeting to discuss the use of Pfizer's Prevnar 13 in adults 65 and older late last week, a CDC advisory committee isn't planning to vote on recommendation of the shot just yet. But when it does, it will have a few things to consider--including Prevnar's long-term cost effectiveness in that population--before giving it a nod.
The partnership may include the use of Pfizer's genetically modified animal models to evaluate the safety and efficacy of therapeutic molecules in oncology, inflammation, immunology, central nervous system and cardiovascular system disorders.
A higher price could get a deal done between Pfizer and AstraZeneca if British regulators play along, but investors aren't convinced that would be a particularly good outcome for either company. The two pharmas aren't far apart on price, and any renewal of negotiations could come as early as August.
AbbVie may be working with some of the same advisers who worked on Pfizer's so-far-failed play for AstraZeneca. But after three rejections from target Shire--the latest totaling about $46.5 billion--it's not about to make Pfizer's same mistakes.
Right now, Eliquis, the new-age clot-fighter from Pfizer and Bristol-Myers Squibb, is in third place in a three-horse race. But as it tries to catch up to rivals Pradaxa and Xarelto--not to mention the $3-billion-per-year sales forecasts analysts slapped on it in its early days--a new recommendation for expanded use in Europe should give it a boost.